Bastion Asset Management Inc. Buys 194,822 Shares of AngioDynamics, Inc. $ANGO

Bastion Asset Management Inc. raised its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 17.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,313,002 shares of the medical instruments supplier’s stock after acquiring an additional 194,822 shares during the period. AngioDynamics makes up 4.3% of Bastion Asset Management Inc.’s investment portfolio, making the stock its 3rd biggest holding. Bastion Asset Management Inc.’s holdings in AngioDynamics were worth $14,107,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. D.A. Davidson & CO. acquired a new position in shares of AngioDynamics in the fourth quarter valued at approximately $1,751,000. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics during the fourth quarter worth $17,978,000. Armistice Capital LLC lifted its holdings in shares of AngioDynamics by 3.9% during the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after purchasing an additional 64,000 shares during the period. Royce & Associates LP grew its position in AngioDynamics by 27.3% in the 4th quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier’s stock valued at $16,274,000 after buying an additional 272,091 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in AngioDynamics in the 4th quarter valued at $204,000. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Stock Performance

NASDAQ:ANGO opened at $14.14 on Friday. The stock has a fifty day moving average price of $12.19 and a two-hundred day moving average price of $11.34. The stock has a market capitalization of $584.41 million, a price-to-earnings ratio of -16.25 and a beta of 0.34. AngioDynamics, Inc. has a 1 year low of $8.36 and a 1 year high of $15.20.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts predict that AngioDynamics, Inc. will post -0.26 EPS for the current year.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics posted record fiscal Q4 and full-year results, with revenue growth, an earnings beat, and expanding gross margin, all of which support the bullish move in the stock. AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
• Positive Sentiment: The company raised its fiscal 2027 sales outlook, suggesting management sees continued momentum in demand and execution. AngioDynamics tops revenue forecasts and raises sales outlook for fiscal 2027 (ANGO)
• Neutral Sentiment: HC Wainwright raised its price target to $19 and kept a Buy rating, reinforcing the stock’s upside case even though the move also reflects that the shares have already appreciated meaningfully. HC Wainwright raised its price target on AngioDynamics
• Negative Sentiment: HC Wainwright also trimmed its Q4 2027 earnings estimate to $0.01 from $0.05, indicating analysts still see only modest near-term profit generation despite the improved outlook. AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

Wall Street Analyst Weigh In

A number of equities analysts have commented on ANGO shares. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. HC Wainwright increased their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Zacks Research downgraded shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.